ArticleACS pharmacology & translational science2026
Myostatin Inhibitory D‑Peptides Induce Skeletal Muscle Hypertrophy along with Alteration of Bioactive Sphingolipid Metabolism.
Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myostatin inhibition is well-known as a promising strategy to induce skeletal muscle hypertrophy. Midsized peptides are currently noted as a new modality in broad drug development. Our previous studies identified a series of myostatin inhibitory peptides, including the 16-mer D-peptide inhibitor MID-35. However, the detailed pharmacological analysis of muscle growth provided by intramuscularly injected MID-35 has not been investigated. Additionally, since sphingosine 1-phosphate (S1P), one of the bioactive sphingolipids, is involved in the regulation of muscle mass, it is vital to explore whether MID-35 treatment affects the S1P metabolism. Here, we analyzed alterations induced by MID-35 administration in the tibialis anterior muscles of young, adult, and aged mice. Muscle differentiation-related markers (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.